AGP Picks
View all

Tech Times of New York: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Times of New York.

Press releases published on November 18, 2026

Tech platforms' business models amplify misogyny and gender-based violence, finds Equality Now report
JabberYak Expands Conference Engagement With New Scavenger Hunt and Analytics
Shield Named to the 2026 Deloitte Technology Fast 500™ for Second Consecutive Year
Gradient Labs brings AI agents for financial services to Google Cloud Marketplace
E&I Brings Procurement Community Together at First-Ever EdPro Summit
Alice & Bob Unveils Accelerated Roadmap on Modular Architecture: 200 Logical Qubits from 3,600 Physical Qubits by 2030
Use.ai Reddit Review of Features for Everyday Projects
Cyberscope Partners with Ment Tech to Strengthen Web3 Security and Blockchain Technology Capabilities
Meetingz.ai Turns Business Conversations into a Shared Business Asset
Claytech Global Founder Gawayne Williams Shares How Faith Guides His Approach to Building Businesses
iMyFone AnyTo Improves Bluetooth Stability in November Updates for Windows and Mac
Yesway Announces Launch of Secondary Public Offering
TTEC Identifies Six CX Trends Businesses Must Prepare for in 2027
Immuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic Cancer
Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid Cancer
Surgery Partners, Inc. Announces Increased Consent Fee in Consent Solicitation Relating to Surgery Center Holdings, Inc.’s 7.250% Senior Notes due 2032
SELLAS Life Sciences meldet positive Ergebnisse der zulassungsrelevanten Phase III-Studie REGAL zu immuntherapeutischem Krebsimpfstoff Galinpepimut-S (GPS), die eine statistisch signifikante und klinisch bedeutsame Verbesserung in Bezug auf…
SELLAS Life Sciences annonce une les résultats positifs de l’étude pivot de phase III REGAL : l’utilisation du vaccin immunothérapeutique contre le cancer, le Galinpepimut-S (GPS), a démontré une amélioration statistiquement significative et…
חברת SELLAS Life Sciences מודיעה על נתונים חיוביים מניסוי ה-REGAL – מחקר מכריע בשלב 3 – המראים כי החיסון האימונותרפי לסרטן, Galinpepimut-S (GPS), הוביל לשיפור מובהק סטטיסטית ומשמעותי מבחינה קלינית בהישרדות הכוללת בקרב חולים עם לוקמיה מיאלואידית חריפה (…
SELLAS Life Sciences Mengumumkan Data Positif dari Uji Klinis Penting Fase 3 REGAL yang Menunjukkan bahwa Vaksin Imunoterapi Kanker Galinpepimut-S (GPS) Memberikan Peningkatan Kesintasan Keseluruhan yang Signifikan Secara Statistik dan Bermakna Secara…

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Tech Times of New York

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.